MRT-2359 for Solid Tumors
Trial Summary
The trial requires that you stop taking certain medications, such as chemotherapy, radiation, or biological cancer therapy, at least 21 days before starting the study treatment. However, if you have prostate cancer, you can continue therapies to maintain low testosterone levels, and pre-menopausal women with hormone-dependent breast cancer can continue therapies for ovarian function suppression.
Eligibility Criteria
Adults over 18 with certain advanced cancers (like lung cancer, neuroendocrine carcinoma, or lymphoma) who've tried other treatments without success. They must be expected to live at least 3 months, be able to perform daily activities with minimal assistance, and use birth control. People can't join if they've had recent cancer treatments that haven't worn off yet or have serious health issues like active infections or heart disease.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Phase 1 Dose Escalation
Participants receive escalating doses of MRT-2359 to determine safety, tolerability, and maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D)
Phase 2 Expansion
Participants are enrolled based on molecular biomarkers stratification or selection to assess preliminary anti-tumor activity of MRT-2359
Follow-up
Participants are monitored for safety and effectiveness after treatment